Attached files

file filename
10-K - ANNUAL REPORT - TENAX THERAPEUTICS, INC.oxbt_10k.htm
EX-31.1 - CERTIFICATION - TENAX THERAPEUTICS, INC.oxbt_ex311.htm
EX-31.2 - CERTIFICATION - TENAX THERAPEUTICS, INC.oxbt_ex312.htm
EX-32.1 - CERTIFICATION - TENAX THERAPEUTICS, INC.oxbt_ex321.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM - TENAX THERAPEUTICS, INC.oxbt_ex231.htm
EX-10.27 - EMPLOYMENT AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex1027.htm
EX-10.23 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex1023.htm
EX-10.35 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex1035.htm
EX-10.33 - RESIGNATION OF EMPLOYMENT AND CONSULTING AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex1033.htm
EX-10.36 - FORM OF INDEMNIFICATION AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex1036.htm
Exhibit 32.2

 
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
 
In connection with the Annual Report of Oxygen Biotherapeutics, Inc. (the “Company”) on Form 10-K for the period ended April 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael B. Jebsen, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
       
Date: July 14, 2011
By:
 /s/ Michael B. Jebsen
 
   
 Michael B. Jebsen
 
   
 Chief Financial Officer
 
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.